Zhang Wenduo, Yang Ruiyue, Yu Xue, Wang Siming, Wang Xinyue, Mu Hongna, Tang Yueming, Li Xianghui, Wang Mo, Yang Chenguang, Li Peng, Li Hongxia, Dong Jun, Chen Wenxiang, Ji Fusui
Department of Cardiology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology of National Health Commission, Beijing, China.
Ann Transl Med. 2022 Jul;10(14):790. doi: 10.21037/atm-22-2834.
The atherosclerotic coronary artery disease (CAD) risk assessment based on conventional risk factors have only moderate performance, and residual risks still exist. Thus, we reported here a cohort study that aims to identify and validate the new biosignatures (especially the metabolomics, lifestyle biomarkers and biological age), and elucidate their predictive effect on CAD and subsequent cardiovascular events.
This prospective, single-center, cohort study commenced in March 2017 and seeks to examine patients undergoing coronary angiography (CAG) at the Beijing Hospital. Patients' baseline demographic and medical history data are captured by questionnaires. Blood samples are taken before CAG for clinical laboratory tests and metabolomics analyses. Traditional CAD risk factors are analyzed by routine assays. CAD-related metabolites from different metabolic pathways and lifestyle biomarkers are measured by liquid chromatography-tandem mass spectrometry methods. Biological ages are calculated based on the laboratory and metabolomics data. The enrolled patients attend annual follow-up examinations for 10 years. The primary end points are the composite end points of major adverse cardiovascular events, including death from any cause, non-fatal myocardial infarction, and non-fatal stroke. Quality management and control are carried out through the entire research process, including standardized baseline and follow-up investigation, intra- and inter-run quality controls for laboratory measurements, etc.
Baseline data of the enrolled 2,970 patients from 2017 to 2020 were collected and are presented in this article. Among them, there were more males (62.5%) than females, and the patients tended to be old and overweight. The percentages of diagnosed hypertension and diabetes were 67.3% and 35.2%, respectively. A total of 8.5% had a family history of premature CAD. Their lipid profiles were within the normal range, probably due to the use of statins.
This study has successfully initiated an investigation into the roles of new biosignatures in predicting CAD among Chinese Han patients undergoing CAG. To the best of our knowledge, this cohort is the first study systematically focusing on the association of lifestyle biomarkers and biological age with CAD risk. Findings from this study will provide biomarkers to discriminate the presence of CAD and to predict subsequent cardiovascular events.
基于传统危险因素的动脉粥样硬化性冠状动脉疾病(CAD)风险评估表现一般,仍存在残余风险。因此,我们在此报告一项队列研究,旨在识别和验证新的生物标志物(尤其是代谢组学、生活方式生物标志物和生物学年龄),并阐明它们对CAD及后续心血管事件的预测作用。
这项前瞻性、单中心队列研究于2017年3月开始,旨在对北京医院接受冠状动脉造影(CAG)的患者进行检查。通过问卷收集患者的基线人口统计学和病史数据。在CAG前采集血样进行临床实验室检查和代谢组学分析。通过常规检测分析传统CAD危险因素。采用液相色谱-串联质谱法测量来自不同代谢途径的CAD相关代谢物和生活方式生物标志物。根据实验室和代谢组学数据计算生物学年龄。纳入的患者进行为期10年的年度随访检查。主要终点是主要不良心血管事件的复合终点,包括任何原因导致的死亡、非致命性心肌梗死和非致命性中风。在整个研究过程中进行质量管理和控制,包括标准化的基线和随访调查、实验室测量的批内和批间质量控制等。
收集了2017年至2020年纳入的2970例患者的基线数据,并在本文中呈现。其中男性(62.5%)多于女性,患者趋于年老且超重。确诊高血压和糖尿病的比例分别为67.3%和35.2%。共有8.5%的患者有早发CAD家族史。他们的血脂水平在正常范围内,可能是由于使用了他汀类药物。
本研究成功启动了一项关于新生物标志物在接受CAG的中国汉族患者中预测CAD作用的调查。据我们所知,该队列是第一项系统关注生活方式生物标志物和生物学年龄与CAD风险关联的研究。本研究结果将提供生物标志物以鉴别CAD的存在并预测后续心血管事件。